Randomized controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users

被引:23
作者
Tucker, T
Fry, CL
Lintzeris, N
Baldwin, S
Ritter, A
Donath, S
Whelan, G
机构
[1] Turning Point Alcohol & Drug Ctr, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Publ Hlth, Parkville, Vic 3052, Australia
[3] Natl Addict Ctr, London, England
[4] Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia
[5] St Vincents Hosp, Melbourne, Vic, Australia
关键词
brief behavioural intervention; hepatitis C virus; injecting drug use; randomized controlled trial;
D O I
10.1111/j.1360-0443.2004.00809.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aim To develop and evaluate a brief intervention for reducing risk behaviours associated with HCV transmission in injecting drug users (IDU). Design Randomized controlled trial of an individually tailored brief behavioural intervention (BBI) (experimental) versus a standardized educational intervention (control). Setting Specialist drug treatment facility in Melbourne, Australia. Participants One hundred and forty-five IDU (aged 18 or over, injecting at least weekly in the preceding 6 months) recruited and randomized to the experimental condition (n = 73) or the control condition (n = 72). Interventions The BBI was based on the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ)-a standardized blood-borne virus risk assessment instrument comprising injecting risk, sexual risk and other skin penetration risk subscales. The BBV-TRAQ was used to identify individual HCV risk practices and to tailor the 30-minute experimental BBI. Control participants received a standardized HCV educational session, using current educational materials. Main outcome measures BBV-TRAQ subscale and total scores and measures of participant satisfaction. Results One hundred and twenty-four participants (86%) were followed-up at 4 weeks ( 7 days). Analyses revealed a significant reduction in HCV risk behaviours for both groups at 1-month follow-up, with participants in the experimental BBI condition reporting higher overall satisfaction with the intervention compared to the control group. Conclusions Both groups reported significant reductions in risk behaviour, indicating that while BBI methods hold promise for HCV education and prevention, they were not demonstrated to be more effective than the provision of standard educational materials. Future research could evaluate the efficacy of the BBV-TRAQ as a risk behaviour intervention and counselling tool in clinical, NSP and peer education settings.
引用
收藏
页码:1157 / 1166
页数:10
相关论文
共 50 条
  • [21] Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?
    de Vos, Anneke S.
    Prins, Maria
    Kretzschmar, Mirjam E. E.
    ADDICTION, 2015, 110 (06) : 975 - 983
  • [22] HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway
    Miller, M
    Mella, T
    Moi, T
    Eskild, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) : 373 - 379
  • [23] Female injecting drug users: Human immunodeficiency virus risk behavior and intervention needs
    Brown, EJ
    JOURNAL OF PROFESSIONAL NURSING, 1998, 14 (06) : 361 - 369
  • [24] High incidence of hepatitis C virus reinfection within a cohort of injecting drug users
    Micallef, J. M.
    Macdonald, V.
    Jauncey, M.
    Amin, J.
    Rawlinson, W.
    van Beek, I.
    Kaldor, J. M.
    White, P. A.
    Dore, G. J.
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 (06) : 413 - 418
  • [25] Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users
    Morice, Yoann
    Cantaloube, Jean-Francois
    Beaucourt, Stephanie
    Barbotte, Laetitia
    De Gendt, Sija
    Goncales, Fernando Lopes
    Butterworth, Lesley
    Cooksley, Graham
    Gish, Robert G.
    Beaugrand, Michel
    Fay, Fabian
    Fay, Oscar
    Gonzalez, Jorge E.
    Martins, Regina Maria Bringel
    Dhumeaux, Daniel
    Vanderborght, Bart
    Stuyver, Lieven
    Sablon, Erwin
    de Lamballerie, Xavier
    Pawlotsky, Jean-Michel
    JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (10) : 1296 - 1303
  • [26] A pilot replication of QUIT, a randomized controlled trial of a brief intervention for reducing risky drug use, among Latino primary care patients
    Gelberg, Lillian
    Andersen, Ronald M.
    Rico, Melvin W.
    Vahidi, Mani
    Rey, Guillermina Natera
    Shoptaw, Steve
    Leake, Barbara D.
    Serota, Martin
    Singleton, Kyle
    Baumeister, Sebastian E.
    DRUG AND ALCOHOL DEPENDENCE, 2017, 179 : 433 - 440
  • [27] Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow
    McDonald, Scott A.
    Hutchinson, Sharon J.
    Cameron, Sheila O.
    Innes, Hamish A.
    McLeod, Allan
    Goldberg, David J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2012, 23 (05) : 353 - 357
  • [28] Hepatitis C treatment uptake and adherence among injecting drug users in the Czech Republic
    Mravcik, V
    Strada, L.
    Reimer, J.
    Schulte, B.
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2014, 63 (04): : 265 - 269
  • [29] DC-SIGN Polymorphisms Associate with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users
    Steba, Gaby S.
    Koekkoek, Sylvie M.
    Vanhommerig, Joost W.
    Brinkman, Kees
    Kwa, David
    Van der Meer, Jan T. M.
    Prins, Maria
    Berkhout, Ben
    Tanck, Michael
    Paxton, William A.
    Molenkamp, Richard
    Schinkel, Janke
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (03) : 353 - 357
  • [30] Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos, Anneke S.
    van der Helm, Jannie J.
    Matser, Amy
    Prins, Maria
    Kretzschmar, Mirjam E. E.
    ADDICTION, 2013, 108 (06) : 1070 - 1081